药学学报, 2021, 56(2): 496-502
引用本文:
于群, 袁佳璐, 翟小田, 马健, 苗庆芳, 甄永苏. 新型抗体偶联药物607-LDM的制备及抗肿瘤活性研究[J]. 药学学报, 2021, 56(2): 496-502.
YU Qun, YUAN Jia-lu, ZHAI Xiao-tian, MA Jian, MIAO Qing-fang, ZHEN Yong-su. Preparation and anti-tumor activity of a novel antibody-drug conjugate 607-LDM[J]. Acta Pharmaceutica Sinica, 2021, 56(2): 496-502.

新型抗体偶联药物607-LDM的制备及抗肿瘤活性研究
于群1, 袁佳璐2,3, 翟小田1, 马健2,3, 苗庆芳1, 甄永苏1
1. 中国医学科学院医药生物技术研究所, 国家卫生健康委员会抗生素生物工程重点实验室, 北京 100050;
2. 抗体药物国家工程研究中心, 上海 201203;
3. 三生国健药业 (上海) 股份有限公司, 上海 201203
摘要:
抗体偶联药物(antibody-drug conjugates,ADCs)是目前肿瘤治疗药物中最重要的种类之一。人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)特异性高表达于乳腺癌和卵巢癌等多种实体肿瘤,已被证实是ADC的理想靶点。力达霉素(lidamycin,LDM)是中国医学科学院医药生物技术研究所自主研发的强效烯二炔抗肿瘤抗生素,其分子具有可拆分和重建的特点,适于用作ADC的“弹头”药物。本研究利用LDM的分子特点,采用特殊“定点偶联”技术,制备药物抗体比(drug-to-antibody ratio,DAR)为2的抗HER2抗体607与力达霉素的ADC 607-LDM,并研究其抗肿瘤活性,结果表明:607-LDM在体外对人卵巢癌SKOV3和乳腺癌BT-474细胞有强烈杀伤活性,还可诱导二者发生细胞凋亡和G2/M期阻滞。在SKOV3裸鼠移植模型中(动物实验符合中国实验动物护理和使用准则,并经中国医学科学院医药生物技术研究所实验动物伦理委员会批准),1.0 mg·kg-1 607-LDM尾静脉注射1次,抑瘤率为72.4%,显著强于单独抗体组(30.2%)、LDM最大耐受剂量组(50.6%)及二者联用组(50.1%)。本研究构建的新型ADC药物607-LDM有望成为治疗HER2阳性肿瘤的候选药物。
关键词:    抗体偶联药物      人表皮生长因子受体2      力达霉素      卵巢癌      乳腺癌      抗肿瘤活性     
Preparation and anti-tumor activity of a novel antibody-drug conjugate 607-LDM
YU Qun1, YUAN Jia-lu2,3, ZHAI Xiao-tian1, MA Jian2,3, MIAO Qing-fang1, ZHEN Yong-su1
1. NHC Key Laboratory of Biotechnology of Antibiotics, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing 100050, China;
2. National Engineering Research Center of Antibody Medicine, Shanghai 201203, China;
3. Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Shanghai 201203, China
Abstract:
Antibody-drug conjugates (ADCs) are one of the most important classes of anticancer therapeutics. Human epidermal growth factor receptor-2 (HER2), which is highly expressed in many types of aggressive cancers including breast and ovarian cancer, has been approved as an ideal target for ADCs. Lidamycin (LDM), developed by Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, is an enediyne-containing antibiotic with potent anti-tumor activity. LDM is a promising payload for ADCs. In the present research, using a special site-directed conjugating technology, we made a novel ADC (607-LDM) with a drug-to-antibody ratio (DAR) of 2 and composed of the anti-HER2 antibody 607 and LDM. The new ADC exhibited potent antitumor activity against human ovarian cancer SKOV3 and breast cancer BT-474 cells. It also induced apoptosis and G2/M arrest. In nude mice with SKOV3 xenografts and a tumor volume of 150-200 mm3, a single intravenous injection 607-LDM at 1 mg·kg-1 induced tumor growth inhibition of 72.4%, which was significant compared to either LDM (50.6%) or antibody (30.2%) treatment alone, or both in combination (50.1%, P<0.05). All animal experiments were performed in accord with National Regulations and approved by the Animal Experiments Ethical Committee of College of Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences. The novel ADC designed in this study, 607-LDM, is a promising candidate for the treatment of HER2-positive cancers.
Key words:    antibody-drug conjugate    human epidermal growth factor receptor 2    lidamycin    ovarian cancer    breast cancer    anti-tumor activity   
收稿日期: 2020-07-21
DOI: 10.16438/j.0513-4870.2020-1225
基金项目: 中国医学科学院医学与健康科技创新工程资助项目(2016-I2M-3-013);北京市自然科学基金项目(7202133).
通讯作者: 苗庆芳,Tel:86-10-83167179,E-mail:miaoqf@sina.com
Email: miaoqf@sina.com
相关功能
PDF(983KB) Free
打印本文
0
作者相关文章
于群  在本刊中的所有文章
袁佳璐  在本刊中的所有文章
翟小田  在本刊中的所有文章
马健  在本刊中的所有文章
苗庆芳  在本刊中的所有文章
甄永苏  在本刊中的所有文章

参考文献:
[1] Birrer MJ, Moore KN, Betella I, et al. Antibody-drug conjugate-based therapeutics:state of the science[J]. J Natl Cancer Inst, 2019, 111:538-549.
[2] Zhang ZB, Wang Y, Bai Y. Consideration of antibody drug conjugates development and regulation[J]. Acta Pharm Sin (药学学报), 2020, 55:1971-1977.
[3] Chau CH, Steeg PS, Figg WD. Antibody-drug conjugates for cancer[J]. Lancet, 2019, 394:793-804.
[4] Beck A, Goetsch L, Dumontet C, et al. Strategies and challenges for the next generation of antibody-drug conjugates[J]. Nat Rev Drug Discov, 2017, 16:315-337.
[5] Shao RG, Zhen YS. Relationship between the molecular composition of C1027, a new macromolecular antibiotic with enediyne chromophore, and its antitumor activity[J]. Acta Pharm Sin (药学学报), 1995, 30:336-342.
[6] Zhen YS, Xue YC, Shao RG. Antitumor activity of the new enediyne antibiotic C1027[J]. Chin J Antibiot (中国抗生素杂志), 1994, 19:164-168.
[7] Elster N, Collins DM, Toomey S, et al. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer[J]. Breast Cancer Res Treat, 2014, 149:5-15.
[8] Miller T, Hosford S. Clinical potential of novel therapeutic targets in breast cancer:CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways[J]. Pharmgenomics Pers Med, 2014, 7:203-215.
[9] Nami B, Maadi H, Wang Z. Mechanisms underlying the action and synergism of trastuzumab and pertuzumab in targeting HER2-positive breast cancer[J]. Cancers (Basel), 2018, 10:342.
[10] Day KC, Hiles GL, Kozminsky M, et al. HER2 and EGFR overexpression support metastatic progression of prostate cancer to bone[J]. Cancer Res, 2016, 77:74-85.
[11] Connell CM, Doherty GJ. Activating HER2 mutations as emerging targets in multiple solid cancers[J]. Esmo Open, 2017, 2:e000279.
[12] Curea FG, Hebbar M, Ilie SM, et al. Current targeted therapies in HER2-positive gastric adenocarcinoma[J]. Cancer Biother Radiopharm, 2017, 32:351-363.
[13] Salvia AL, Lopez-Gomez V, Garcia-Carbonero R. HER2-targeted therapy:an emerging strategy in advanced colorectal cancer[J]. Expert Opin Investig Drugs, 2019, 28:29-38.
[14] Black JD, Salvatore L, Emiliano C, et al. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas[J]. Br J Cancer, 2015, 113:1020-1026.
[15] Smith MB, Reardon J, Olson EM. Pertuzumab for the treatment of patients with previously untreated HER2-positive metastatic breast cancer[J]. Drugs Today (Barc), 2012, 48:713-722.
[16] Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer[J]. N Engl J Med, 2015, 372:724-734.
[17] Wang H, Wang W, Xu Y, et al. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells[J]. Cancer Sci, 2017, 108:1458-1468.
[18] Boylan NJ, Zhou W, Proos RJ, et al. Conjugation site heterogeneity causes variable electrostatic properties in Fc conjugates[J]. Bioconjug Chem, 2013, 24:1008-1016.
[19] Wang R, Li L, Zhang S, et al. A novel enediyne-integrated antibody-drug conjugate shows promising antitumor efficacy against CD30+ lymphomas[J]. Mol Oncol, 2018, 12:339-355.
相关文献:
1.蔡琳 高瑞娟 郭效忠 李毅 甄永苏.力达霉素辅基蛋白与人体乳腺癌结合作用的组织芯片研究[J]. 药学学报, 2010,45(5): 582-588